• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Immunocore Holdings Plc ADR (NQ: IMCR )

    35.88 +1.25 (+3.61%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Aug 30, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 812,668
    Open 35.00
    Bid (Size) 35.10 (1)
    Ask (Size) 37.50 (1)
    Prev. Close 34.63
    Today's Range 34.70 - 35.99
    52wk Range 33.05 - 76.98
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Immunocore announces transition of Chief Financial Officer
    From Immunocore Holdings plc
    Via GlobeNewswire
    The Latest Analyst Ratings For Immunocore Hldgs
    Via Benzinga

    Performance

    YTD
    -49.92%
    -49.92%
    1 Month
    -9.62%
    -9.62%
    3 Month
    -26.75%
    -26.75%
    6 Month
    -46.77%
    -46.77%
    1 Year
    -36.24%
    -36.24%

    More News

    Read More
    Deep Dive Into Immunocore Hldgs Stock: Analyst Perspectives (9 Ratings)
    Via Benzinga
    Immunocore reports second quarter financial results and provides a business update
    From Immunocore Holdings plc
    Via GlobeNewswire
    3 Small-Cap Stocks with Significant Growth Potential
    Via InvestorPlace
    Peeling Back The Layers: Exploring Immunocore Hldgs Through Analyst Insights
    Via Benzinga
    Analyst Expectations For Immunocore Hldgs's Future
    Via Benzinga
    Where Immunocore Hldgs Stands With Analysts
    Via Benzinga
    Immunocore to report second quarter 2024 financial results and host call on August 8, 2024
    From Immunocore Holdings plc
    Via GlobeNewswire
    Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma
    From Immunocore Holdings plc
    Via GlobeNewswire
    Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response
    From Immunocore Holdings plc
    Via GlobeNewswire
    Immunocore Hldgs Stock: A Deep Dive Into Analyst Perspectives (8 Ratings)
    Via Benzinga
    Key Takeaways From Immunocore Hldgs Analyst Ratings
    Via Benzinga
    Why Science Applications International Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Via Benzinga
    Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024
    From Immunocore Holdings plc
    Via GlobeNewswire
    Immunocore to present at the Jefferies Global Healthcare Conference
    From Immunocore Holdings plc
    Via GlobeNewswire
    Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma
    From Immunocore Holdings plc
    Via GlobeNewswire
    Why NetEase Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Via Benzinga
    IMCR Stock Earnings: Immunocore Hldgs Misses EPS, Misses Revenue for Q1 2024
    Via InvestorPlace
    Immunocore reports first quarter financial results and provides a business update
    From Immunocore Holdings plc
    Via GlobeNewswire
    Immunocore announces upcoming presentation and posters at ASCO 2024
    From Immunocore Holdings plc
    Via GlobeNewswire
    Immunocore to present at upcoming investor conferences
    From Immunocore Holdings Limited
    Via GlobeNewswire
    Billionaire’s Biotech Bets: 3 Stocks Dominating Bill Gates’ Portfolio
    Via InvestorPlace
    Immunocore presented two posters at CROI 2024
    From Immunocore Holdings Limited
    Via GlobeNewswire
    Immunocore to present at upcoming investor conferences
    From Immunocore Holdings Limited
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.